1. Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
2. ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the firs
3. Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2010
   Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
4. Anavex comments on new Alzheimer’s disease diagnostic guidelines
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated
5. Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
6. Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
   Sources News Release
   Resource Type: Article/Report/Letter
   Published: 2011
   Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by the German regulatory health authority, BfArM. The
7. ART Advanced Research Technologies Inc.
   Media Profile in Sources
   Resource Type: Organization
   
8. Canadian AIDS Treatment Information Exchange (CATIE)
   Media Profile in Sources
   Resource Type: Organization
   
9. Networks of Centres of Excellence of Canada
   Media Profile in Sources
   Resource Type: Organization
   

Experts on Pharmaceutical Research in the Sources Directory

1. CATIE